DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT05786716 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Haematological Malignancy
Colorectal Neoplasms
Urinary Bladder Neoplasm
Gallbladder Neoplasms
Salivary Gland Neoplasm
Lung Neoplasm
Pancreatic Neoplasm
Ovarian Neoplasms
Prostatic Neoplasm
Skin Neoplasm
Solid Tumour

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab

Sponsor

Cancer Research UK

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]